ReShape Lifesciences to Host First Quarter 2019 Conference Call on May 20, 2019

SAN CLEMENTE, CA / ACCESSWIRE / May 20, 2019 / ReShape Lifesciences Inc. (OTCQB: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the first quarter of 2019 on Monday, May 20, 2019 at 1:30 PM Pacific Time.

Individuals interested in listening to the conference call may do so by dialing (877) 280-7473 for domestic callers or (707) 287-9370 for international callers, using Conference ID: 3557379. To listen to a live webcast or a replay, please visit the investor relations section of the Company website at: ir.reshapelifesciences.com.

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Investor Contact:

Scott Youngstrom
Chief Financial Officer
ReShape Lifesciences Inc.
949-429-6680 x106
syoungstrom@reshapelifesci.com

or

Debbie Kaster
Investor Relations
Gilmartin Group
415-937-5403
debbie@gilmartinir.com

SOURCE: ReShape Lifesciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/545929/ReShape-Lifesciences-to-Host-First-Quarter-2019-Conference-Call-on-May-20-2019

user

Recent Posts

PRIVACY ALERT: Tri-Century Eye Care Under Investigation for Data Breach of 200,000 Records

SAN FRANCISCO, Dec. 9, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a…

6 minutes ago

Immortal Dragons Backs Etheros Pharmaceuticals: Targeting Aging-Related Disease with Breakthrough Catalytic Antioxidants

SINGAPORE, Dec. 9, 2025 /PRNewswire/ -- Immortal Dragons, the $40 million longevity-focused innovation fund, today…

6 hours ago

Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care

VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:…

6 hours ago

Campo Indictment Exposes DEA Rotted From Within – While Medical Cannabis Research and Patients Wait Seven Years

A Federal Indictment That Reads Like a Narco-State ThrillerDEA corruption reaches new levels with the…

9 hours ago

Most Americans With OCD Never Receive Effective Treatment, Landmark Study Finds

Analysis by the International OCD Foundation highlights widespread gaps in diagnosis and care BOSTON, MASSACHUSETTS…

9 hours ago